Experts in the treatment of headaches note the positive perception of new NovaMedica drugs by the medical community

At the 15^th anniversary applied research conference New Possibilities in Diagnostics and Treatment of Headaches in St. Petersburg, leading Russian experts noted the positive perception by the medical community of NovaMedica’s new products in the field of pain therapy – Relonova^® and Difendum^®.

The conference took place on October 21 and was dedicated to current issues in diagnostics of various types of headaches, sharing information on new approaches to the choice of treatment options, and innovative therapeutic methods.

The symposium held as part of the conference with the support of NovaMedica was aimed at providing doctors with the most up-to-date information about modern methods of treating migraine and migraine-type headaches. The speakers, renowned experts in this therapeutic area, shared with participants both their practical experience and the latest scientific data. They also noted the significance of the launch in the Russian market of the new NovaMedica drugs, Relonova^® (INN rizatriptan) and Difendum^® (INN diclofenac potassium), which will help them provide better care to their patients.

Gyuzal TABEEVA (Doctor of Medical Sciences), Professor of the Department of Nervous System Diseases and Neurosurgery at the Institute of Clinical Medicine of the Sechenov First Moscow State Medical University, President of the Russian Headache Society, spoke on the “Treatment of Migraine. Standards and Stratification”. She noted the growing role of rizatriptans in this therapy.

According to a recent study, rizatriptan is one of the three triptans that come closest to the characteristics of an ideal triptan,” Professor Tabeeva said in her speech.

Alexander AMELIN (Doctor of Medical Sciences), Professor of the Department of Neurology with the clinic of the Pavlov St. Petersburg State Medical University, member of the Presidium of the Russian Association for the Study of Pain, member of the Presidium of the Russian Headache Society, presented the topic “Treatment of Migraine Attacks: Aspects of Choosing an Effective Pain Relief Strategy”.

Speaking on the difficulties of choosing a therapy option to stop a migraine attack, Professor Amelin noted that “the consistency of the effect from episode to episode makes rizatriptan stand out among drugs of this class, which is very valuable for our patients.”

Eduard YAKUPOV (Doctor of Medical Sciences), Professor, Head of the Professor Yakupov Neuroclinic and Education Center, Honored Doctor of the Republic of Tatarstan, in his speech raised the issues of searching for nonspecific drugs for the treatment of migraine.​

He believes that “NSAIDs are one of the most common groups of drugs purchased by patients with headaches. And Difendum can take a notable place among NSAIDs as a drug in a convenient dosage form, with good efficiency and high speed of action.”

The information that the speakers shared with the audience was received with great interest by the symposium participants, who not only included neurologists, cephalologists, migraine experts, but also specialists of a broader profile – family doctors and general physicians.

Over the past 15 years, the conference has gained a well-deserved prestige in the medical and pharmaceutical community of Russia as one of the key events dedicated to the issues of headache. 

For information:

Relonova^® is an innovative drug based on the rizatriptan molecule indicated for the relief of migraine attacks (headaches and accompanying symptoms). Relonova^® is NovaMedica’s own-development product, which is manufactured in Russia.

Difendum^® is the first drug in Russia based on diclofenac potassium indicated for the treatment of pain syndrome, including headaches, in the form of soft gelatin capsules that ensure its fast action and convenient administration.